Clinical trials: Mono
Acute Mania in Bipolar Disorder
Quetiapine Fumarate (Seroquel) as Mono-Therapy or Adjunct to Lithium in the Treatment of Patients With Acute Mania in Bipolar Disorder
To compare the efficacy and safety of quetiapine fumarate given as mono-therapy or adjunct therapy to lithium in the treatment of patients with acute mania in bipolar disorder.
- Trial name
- MANIA (NCT00672490)
- Testing
- Quetiapine Fumarate, Lithium
- Where
- 16 sites in China
- Volunteers
- 376 people
- Sponsor
- AstraZeneca
Type2 Diabetes, High Blood Sugar
Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus
This is a long term, single arm, open label study to evaluate the safety and efficacy of dapagliflozin as monotherapy or in combination therapy with other anti diabetic drug in Japanese subjects with type 2 diabetes mellitus who…
- Trial name
- NCT01294436
- Testing
- Dapagliflozin
- Where
- 38 sites in Japan
- Volunteers
- 728 people
- Sponsor
- AstraZeneca
Dysmenorrhea
Efficacy and Safety Study of Low Dose Oral Contraceptive Pill to Treat Primary Dysmenorrhea
The purpose of this study is to determine whether combination oral contraceptive pill of norethindrone and ethinyl estradiol is effective in the treatment of primary dysmenorrhea.
- Trial name
- NCT00746096
- Testing
- IKH-01
- Volunteers
- 115 people
- Sponsor
- Nobelpharma
Rheumatoid Arthritis
IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA
The purpose of the study is to better understand the factors present in the cells of inflamed joints of patients with arthritis that may cause rheumatoid arthritis.
- Trial name
- NCT02451748
- Testing
- Lab Work, Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg), Certolizumab pegol (CDP870, tradename Cimzia)
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Illinois Chicago
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)
The main purpose of this study is to investigate the efficacy and safety of Tirzepatide monotherapy in Chinese participants with Type 2 Diabetes.
- Trial name
- NCT05963022
- Testing
- Tirzepatide
- Where
- 28 sites in China
- Volunteers
- 206 people
- Sponsor
- Eli Lilly and Company
Hypertension
TElmisartan and AMlodipine Single Pill sTudy With Patients Not on Goal With Mono rAas Therapy-switch
The general aim of this trial to determine the efficacy as measured by the percentage of patients reaching blood pressure goal at the end of the treatment period at 12 weeks.
- Trial name
- NCT01134393
- Testing
- telmisartan/amlodipine
- Where
- 47 sites in Germany, Italy and 3 more
- Volunteers
- 502 people
- Sponsor
- Boehringer Ingelheim
HIV Dementia
Modulation of Monocyte Activation by Atorvastatin in HIV Infection
Activated monocytes play a key role in the pathogenesis of HIV-associated neurocognitive disorders (HAND). Individuals with HAND have expanded populations of activated monocytes.
- Trial name
- NCT01263938
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Pennsylvania
Diabetic Macular Edema
A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension Study
CRFB002D2301: The core study was designed to confirm the efficacy and safety of ranibizumab (0.5 mg) as adjunctive therapy when added to laser photocoagulation and/or mono-therapy in patients with visual impairment due to…
- Trial name
- RESTORE (NCT00687804)
- Testing
- Ranibizumab, Laser
- Where
- 13 sites in Australia, Belgium and 11 more
- Volunteers
- 345 people
- Sponsor
- Novartis
Infectious Mononucleosis
Activity of Valomaciclovir in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection
This will be a randomized, placebo-controlled, double-blind single-center proof of concept study to evaluate the anti-EBV activity of 4 grams of valomaciclovir (2 grams BID) for 21 days in subjects with infectious mononucleosis…
- Trial name
- Mono6 (NCT00575185)
- Testing
- Valomaciclovir
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Minnesota
HIV Dementia
Downmodulating Monocyte Activation for HIV-1 Associated Neurocognitive Disorders (HAND)
HIV associated neurological disorders (HAND), are a major problem even in ART treated people. HAND results from chronic inflammation which is largely attributed to expansion and activation of monocytes.
- Trial name
- NCT01600170
- Testing
- Atorvastatin (generic Lipitor)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Pennsylvania
Non-small Cell Lung Cancer
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
The purpose of this study is to compare the anti-tumor efficacy of oral single-agent rociletinib, as measured by investigator assessment of the PFS, with that of single-agent cytotoxic chemotherapy in patients with EGFR-mutated…
- Trial name
- NCT02322281
- Testing
- Rociletinib, Pemetrexed or gemcitabine or paclitaxel or docetaxel
- Where
- 80 sites in United States, Australia and 8 more
- Volunteers
- 149 people
- Sponsor
- Clovis Oncology, Inc.
Hepatitis C, HIV Coinfection
Supporting Treatment Outcomes Among PWID
The goal of this study is to improve HCV care continuum outcomes for people who inject drugs (PWID), reduce potential onward transmission to others and improve HIV outcomes among those who are HIV/HCV coinfected.
- Trial name
- STOP-C (NCT04652804)
- Testing
- Low intensity HCV treatment adherence support, Medium intensity HCV treatment adherence support, High intensity HCV treatment adherence support
- Where
- India
- Volunteers
- 3,000 people
- Sponsor
- Johns Hopkins University
Healthy Volunteers
Investigation of a New Compression Bandage System Combining Skin Protection, Padding and Compression in One Single Bandage and Comparing to an Existing One-component Bandage.
The goal of this study is to learn about the pressure that can be maintained by a new compression bandage over the course of seven days in healthy volunteers.
- Trial name
- NCT06728137
- Where
- Italy
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Lohmann & Rauscher
Type 2 Diabetes Mellitus
An Extension Protocol to Evaluate Dose Comparisons of Leucine-Metformin Combinations in Type 2 Diabetic Patients
Study NS-0100-01E is an extension of Study NS-01-0100 designed to assess safety and longer term effect (i.e., additional 8 weeks) of various fixed-dose leucine and metformin combinations (NS-0100) versus standard metformin…
- Trial name
- NCT02435277
- Testing
- Low Metformin, Mid Metformin, High Metformin
- Where
- 9 sites in United States
- Volunteers
- 50 people
- Sponsor
- NuSirt Biopharma
HIV
Effects of Raltegravir Based Regimen on Platelet Reactivity, Platelet-monocyte Aggregation and Immune Activation
Cardiovascular disease (CVD) has emerged as a leading cause of morbidity and mortality in HIVinfected individuals. The precise mechanisms underlying this increased cardiovascular risk remain to be elucidated.
- Trial name
- RAPID (NCT02383355)
- Testing
- Raltegravir, Continuation of own regimen
- Volunteers
- 40 people
- Sponsor
- Radboud University Medical Center
Seasonal Allergic Rhinitis
Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen Extract
The objective of this study is to assess the effect of grass pollen extract SLIT tablets on the Rhinoconjunctivitis Total Symptom Score (RTSS) of the six rhinoconjunctivitis symptoms in response to grass pollen challenge after…
- Trial name
- NCT00619827
- Testing
- 300 IR grass pollen allergen extract tablet
- Where
- Austria
- Volunteers
- 89 people
- Sponsor
- Stallergenes Greer
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)
The purpose of this study is to compare the benefits and risks of lixisenatide (AVE0010) used as 2-step initiation regimen and 1-step initiation regimen in Japan, over a period of 24 weeks of treatment, followed by an extension…
- Trial name
- GETGOAL-MONO (NCT00905255)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector
- Where
- Japan
- Volunteers
- 69 people
- Sponsor
- Sanofi
Healthy
Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and Female
The purpose of this trial is to investigate bioequivalence of a newly developed fixed dose combination (FDC) tablet containing empagliflozin and metformin extended release compared to the free combination of empagliflozin and…
- Trial name
- NCT02266472
- Testing
- metformin, empagliflozin/metformin, empagliflozin
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Malaria
Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection
This study will assess efficacy, safety , tolerability and PK in uncomplicated adult malaria patients with P. vivax or P. falciparum infection after 3 day dosing with KAF156 at 400 mg/day (Part 1) and single dosing with KAF156 at…
- Trial name
- NCT01753323
- Testing
- KAF156
- Where
- 5 sites in Thailand, Vietnam
- Volunteers
- 43 people
- Sponsor
- Novartis Pharmaceuticals
Non-myeloid Malignancies, Chemotherapy Induced Anaemia
A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) as Mono Therapy (Without Erythropoiesis Stimulating Agents) in Comparison With Oral Iron Sulfate in Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia (CIA)
The purpose of this study is to compare the efficacy and safety of intravenous iron therapy with oral iron therapy in patients with cancer and chemotherapy induced anaemia.
- Trial name
- NCT01145638
- Testing
- iron isomaltoside 1000, iron sulphate
- Where
- India
- Volunteers
- 350 people
- Sponsor
- Pharmacosmos A/S